MRI Targeted Prostate Biopsy | Exceptional Targeting Accuracy

Home / KOELIS Trinity^® MRI/US Fusion / Exceptional Targeting Accuracy

Proven Biopsy Accuracy — Targeting as Precise as 2.3 mm¹

KOELIS Trinity^® is a leading MRI/ultrasound fusion biopsy system with demonstrated prostate biopsy accuracy as precise as 2.3 mm, as evidenced from a prospective study of Cognitive and Elastic Fusion Registration Transrectal Biopsies.¹ Unlike other technologies that track the movement of the probe (robotic technology or electromagnetic sensors), KOELIS Trinity^® automatically tracks patient movement and prostate deformation during the procedure –helping clinicians achieve the highest level of accuracy available.

As precise as 2.3mm accuracy

KOELIS Trinity^® Automatically Compensates for Prostate and Patient Movement

KOELIS Trinity^® delivers real-time 3D MRI/ultrasound fusion to improve prostate biopsy accuracy and cancer detection rates. The system employs our proprietary Organ-Based Tracking Fusion^® (OBT) technology that tracks the prostate, not the probe. OBT Fusion^® automatically compensates for patient and prostate movement with no need for an additional technician to manually realign imagery. The same prospective study concluded that deformable MR imaging/transrectal US image registration by KOELIS Trinity^® achieved a higher precision and depicted cancer in more patients than the cognitive freehand technique.

Improve Cancer Detection Rates with MRI Targeted Prostate Biopsy

While transrectal or transperineal ultrasound (TRUS) biopsy is typically used to determine the presence of prostate cancer and establish the corresponding prognosis, MRI/US fusion biopsy technology has been proven to outperform the conventional TRUS approach in the detection of significant cancer by 46%.² Conventional biopsy cancer detection rates are relatively low in technical terms as compared to “targeted” biopsies made possible by the fusion of ultrasound images of the prostate with MRI scans or CT/PET sequences, in real time during the procedures.

References:

1. Mean precision was 2.3 mm (95% confidence interval: 1.8 mm, 3.3 mm). Positive cores were closer to the center than were negative cores (dCC: 1.7 mm vs 3.1 mm, respectively; P = .025) https://pubmed.ncbi.nlm.nih.gov/29361246/ Precision Matters in MR Imaging-targeted Prostate Biopsies: Evidence from a Prospective Study of Cognitive and Elastic Fusion Registration Transrectal Biopsies François Cornud , Mathieu Roumiguié, Nicolas Barry de Longchamps , Guillaume Ploussard , Eric Bruguière , Daniel Portalez, Bernard Malavaud.

2. Martini, A., Cumarasamy, S., & Tewari, A. K. (2018). MRI-targeted biopsy for prostate-cancer diagnosis. N Engl J Med, 379(589), 10-1056.